NextCell Pharma AB (OSTO:NXTCL) Cyclically Adjusted FCF per Share: kr-1.05 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:NXTCL NextCell Pharma AB OSTO:NXTCL
42 GF Score
Price kr1.00
GF Value kr0.90
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is NextCell Pharma AB Cyclically Adjusted FCF per Share?

NextCell Pharma AB OSTO:NXTCL -2.72% 42 Cyclically Adjusted FCF per Share is kr-1.05 as of Dec. 2025. GuruFocus rates OSTO:NXTCL with a GF Score™ of 42/100 and a GF Value™ of kr0.90 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

NextCell Pharma AB's adjusted free cash flow per share for the three months ended in Dec. 2025 was kr-0.091. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-1.05 for the trailing ten years ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-13), NextCell Pharma AB's current stock price is kr1.002. NextCell Pharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2025 was kr-1.05. NextCell Pharma AB's Cyclically Adjusted Price-to-FCF of today is .


NextCell Pharma AB  (OSTO:NXTCL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


NextCell Pharma AB Cyclically Adjusted FCF per Share Related Terms


NextCell Pharma AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for NextCell Pharma AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NextCell Pharma AB Cyclically Adjusted FCF per Share Chart

NextCell Pharma AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NextCell Pharma AB Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.05

OSTO:NXTCL vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, NextCell Pharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NextCell Pharma AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NextCell Pharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where NextCell Pharma AB's Cyclically Adjusted Price-to-FCF falls into.


OSTO:NXTCL
42GF Score
NextCell Pharma AB OSTO:NXTCL
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NextCell Pharma AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NextCell Pharma AB's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-0.091/133.3900*133.3900
=-0.091

Current CPI (Dec. 2025) = 133.3900.

NextCell Pharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201508 0.000 99.829 0.000
201605 -0.168 100.914 -0.222
201608 -0.164 100.968 -0.217
201611 -0.202 101.517 -0.265
201702 -0.044 102.037 -0.058
201705 -0.435 102.679 -0.565
201708 -0.502 103.138 -0.649
201711 -0.251 103.413 -0.324
201802 -0.555 103.678 -0.714
201805 -0.024 104.632 -0.031
201808 -0.220 105.197 -0.279
201811 -0.449 105.443 -0.568
201902 -0.233 105.641 -0.294
201905 -0.272 106.895 -0.339
201908 -0.112 106.716 -0.140
201911 -0.161 107.345 -0.200
202002 -0.207 106.742 -0.259
202005 -0.195 106.882 -0.243
202008 -0.172 107.571 -0.213
202011 -0.174 107.549 -0.216
202102 -0.192 108.190 -0.237
202105 -0.177 108.838 -0.217
202108 -0.140 109.780 -0.170
202111 -0.133 111.069 -0.160
202202 -0.317 112.834 -0.375
202205 -0.259 116.746 -0.296
202208 -0.057 120.573 -0.063
202211 -0.208 123.803 -0.224
202302 -0.249 126.321 -0.263
202305 -0.425 128.034 -0.443
202308 -0.309 129.560 -0.318
202311 -0.291 130.958 -0.296
202402 -0.297 132.046 -0.300
202405 -0.282 132.818 -0.283
202408 -0.162 132.052 -0.164
202411 -0.175 133.000 -0.176
202502 -0.110 133.744 -0.110
202505 -0.133 133.064 -0.133
202508 -0.114 133.440 -0.114
202512 -0.091 133.390 -0.091

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-1.05 mean?
NextCell Pharma AB (OSTO:NXTCL) has a Cyclically Adjusted FCF per Share of kr-1.05 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on NextCell Pharma AB and its competitors.
Is NextCell Pharma AB's Cyclically Adjusted FCF per Share too high?
NextCell Pharma AB's current Cyclically Adjusted FCF per Share is kr-1.05. Overall, NextCell Pharma AB has a GF Score™ of 42/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NextCell Pharma AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
NextCell Pharma AB's Cyclically Adjusted FCF per Share of kr-1.05 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on NextCell Pharma AB and its competitors. NextCell Pharma AB's current Cyclically Adjusted FCF per Share is kr-1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NextCell Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, NextCell Pharma AB (OSTO:NXTCL) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.90, compared to a current price of kr1.00 — trading 11.3% above its estimated fair value. The current Cyclically Adjusted FCF per Share is kr-1.05. NextCell Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For NextCell Pharma AB (OSTO:NXTCL), the current Cyclically Adjusted FCF per Share is kr-1.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NextCell Pharma AB (OSTO:NXTCL) Overvalued in 2026?

Based on GuruFocus' analysis, NextCell Pharma AB stock appears to be overvalued. The current stock price of kr1.00 is trading 11.3% above its estimated GF Value™ of kr0.90. GuruFocus considers NextCell Pharma AB to be Modestly Overvalued.

Key valuation signals for OSTO:NXTCL:

  • Cyclically Adjusted FCF per Share: kr-1.05
  • GF Value™: kr0.90 vs. price of kr1.00 (11.3% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the OSTO:NXTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NextCell Pharma AB Business Description

Other Exchanges 65G:Germany
Address Karolinska Institutet Science Park, Halsovagen 7, Huddinge, SWE, 14157
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
42GF Score

Get the complete analysis for OSTO:NXTCL

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.00
Price
kr0.90
GF Value